PMID- 22661187
OWN - NLM
STAT- MEDLINE
DCOM- 20121123
LR  - 20220330
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Linking)
VI  - 64
IP  - 2
DP  - 2012
TI  - Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris 
      patients after percutaneous coronary intervention.
PG  - 360-8
AB  - BACKGROUND: Our aim was to prospectively assess the potential influence of 
      pantoprazole therapy on the antiplatelet effects of acetylsalicylic acid (ASA) 
      and clopidogrel (CLO) in stable angina pectoris (SAP) patients after percutaneous 
      coronary intervention (PCI). METHODS: Forty-four patients with SAP (CCS I-III) 
      and successful PCI with stent implantation were enrolled into the study. The 
      patients were divided into group proton pump inhibitors (PPI): 23 patients with 
      indications for PPI (F/M = 9/14; age = 64 +/- 9; standard therapy + 20 mg 
      pantoprazole) and the control group (group C): 21 patients (F/M = 6/15; age = 64 
      +/- 8; standard therapy). The platelet function analysis in whole blood based on 
      impedance aggregometry (ASPI, COL, ADP, TRAP tests) using Multiplate--V2.02.11 
      was performed 18-24 h after the PCI + CLO loading dose (600 mg) and 30 days after 
      PCI. RESULTS: Both baseline patient characteristics and clinical outcomes were 
      comparable between the study groups. There were no differences in the mean values 
      of the platelets (PTL) tests measured at the 30(th) day after PCI between both 
      groups (PPI vs. C: ASPI: 24.6 +/- 10.0 vs. 42.1 +/- 14.8 U, COL: 32.9 +/- 8.6 vs. 34.0 
      +/- 7.7 U, ADP: 26.8 +/- 12.4 vs. 30.4 +/- 8.1 U, TRAP: 78.7 +/- 16.6 vs. 78.1 +/- 22.6 U, 
      p = ns). The mean delta values of the PTL tests (18-24 h post-PCI/30 days 
      post-PCI) were also comparable between the groups. The PTL aggregometry results 
      were related to time (ADP, ASPI, TRAP vs. time, p = 0.001; COL vs. time, p = 
      0.03)--the baseline values of ADP, ASPI, COL and TRAP tests were smaller than 
      those measured after the one-month observation. CONCLUSION: Pantoprazole 
      treatment does not impair the efficacy of dual antiplatelet therapy in patients 
      with SAP after PCI.
FAU - Mizia-Stec, Katarzyna
AU  - Mizia-Stec K
AD  - 1st Deparment of Cardiology, Medical University of Silesia, Ziolowa 45/47, PL 
      40-635 Katowice, Poland. kmizia@op.pl
FAU - Haberka, Maciej
AU  - Haberka M
FAU - Mizia, Magdalena
AU  - Mizia M
FAU - Lasota, Bartosz
AU  - Lasota B
FAU - Kunecki, Marcin
AU  - Kunecki M
FAU - Gieszczyk, Klaudia
AU  - Gieszczyk K
FAU - Chmiel, Artur
AU  - Chmiel A
FAU - Najda, Jacek
AU  - Najda J
FAU - Kyrcz-Krzemien, Slawomira
AU  - Kyrcz-Krzemien S
FAU - Gasior, Zbigniew
AU  - Gasior Z
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - D8TST4O562 (Pantoprazole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Angina, Stable/blood/*surgery
MH  - Angioplasty, Balloon, Coronary/*adverse effects
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Clopidogrel
MH  - Coronary Thrombosis/*etiology/prevention & control
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gastrointestinal Hemorrhage/prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pantoprazole
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/administration & dosage/*adverse effects/therapeutic use
MH  - Stents
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2012/06/05 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/06/05 06:00
PHST- 2011/05/10 00:00 [received]
PHST- 2011/12/05 00:00 [revised]
PHST- 2012/06/05 06:00 [entrez]
PHST- 2012/06/05 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S1734-1140(12)70776-4 [pii]
AID - 10.1016/s1734-1140(12)70776-4 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2012;64(2):360-8. doi: 10.1016/s1734-1140(12)70776-4.